(Q42610530)

English

Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval

scientific article published on 29 January 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval (English)

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

1 reference

based on heuristic

inferred from title

schizoaffective disorder

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Georges M Gharabawi

1

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

Natalie C Gearhart

2

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

Robert A Lasser

3

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

Ramy A Mahmoud

4

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

Young Zhu

5

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

Erik Mannaert

6

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

Ineke Naessens

7

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

Cynthia A Bossie

8

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

Mary Kujawa

9

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

George M Simpson

10

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

publication date

29 January 2007

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

Annals of General Psychiatry

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

6

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

3

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

A visual guide to expected blood levels of long-acting injectable risperidone in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803785

27 May 2018

Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803785

27 May 2018

Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803785

27 May 2018

Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803785

27 May 2018

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803785

27 May 2018

Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803785

27 May 2018

Costs and benefits of two doses of fluphenazine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803785

27 May 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803785

27 May 2018

A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803785

16 August 2018

Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803785

16 August 2018

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803785

16 August 2018

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803785

16 August 2018

Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803785

16 August 2018

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803785

16 August 2018

A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803785

16 August 2018

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803785

16 August 2018

Identifiers

10.1186/1744-859X-6-3

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1744-859x-6-3

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42610530&oldid=2205538060"